<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02401048</url>
  </required_header>
  <id_info>
    <org_study_id>PCYC-1136-CA</org_study_id>
    <nct_id>NCT02401048</nct_id>
  </id_info>
  <brief_title>A Multi-Center Study of Ibrutinib in Combination With MEDI4736 in Subjects With Relapsed or Refractory Lymphomas</brief_title>
  <official_title>A Multi-Center Open-Label Study of the Bruton's Tyrosine Kinase (BTK) Inhibitor, Ibrutinib, in Combination With MEDI4736, in Subjects With Relapsed or Refractory Lymphomas</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Pharmacyclics LLC.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>AstraZeneca</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
    <collaborator>
      <agency>Janssen Research &amp; Development, LLC</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Pharmacyclics LLC.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to evaluate the efficacy, safety and tolerability of the
      combination treatment of ibrutinib and MEDI4736 in patients with relapsed or refractory
      lymphomas.
    </textblock>
  </brief_summary>
  <overall_status>Active, not recruiting</overall_status>
  <start_date>May 2015</start_date>
  <completion_date type="Anticipated">July 2018</completion_date>
  <primary_completion_date type="Anticipated">April 2018</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Factorial Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Phase 1b/2 (Number and type of adverse events)</measure>
    <time_frame>Approximately 12 months</time_frame>
    <description>Number and type of adverse events</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Phase Ib/2 (Overall response rate)</measure>
    <time_frame>Approximately 12 months</time_frame>
    <description>Overall response rate</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Phase Ib/2 (Pharmacokinetics of ibrutinib) Cmax</measure>
    <time_frame>Approximately 2 months</time_frame>
    <description>Cmax: The peak plasma concentration of ibrutinib after administration</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Phase Ib/2 (Pharmacokinetics of ibrutinib) AUC0-24</measure>
    <time_frame>Approximately 2 months</time_frame>
    <description>AUC0-24: The area under the plasma concentration-time curve of ibrutinib after administration from time zero to 24 hours</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Phase Ib/2 (Pharmacokinetics of MEDI4736) Cmax</measure>
    <time_frame>Approximately 8 months</time_frame>
    <description>Cmax: The peak plasma concentration of MEDI4736 after administration</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Phase Ib/2 (Pharmacokinetics of MEDI4736) Ctrough</measure>
    <time_frame>Approximately 8 months</time_frame>
    <description>Ctrough: The trough plasma concentration of MEDI4736</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Phase Ib/2 (Pharmacodynamics of ibrutinib) Btk occupancy after ibrutinib administration</measure>
    <time_frame>Approximately 1 month</time_frame>
    <description>Btk occupancy after ibrutinib administration</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Anticipated">109</enrollment>
  <condition>Diffuse Large B-Cell Lymphoma</condition>
  <condition>Follicular Lymphoma</condition>
  <arm_group>
    <arm_group_label>Phase 1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Dose determination safety cohort</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Phase 2: Follicular lymphoma expansion cohort:</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Will use the recommended Phase 2 doses determined in the Phase 1 portion</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Phase 2: Diffuse large B-cell lymphoma expansion cohort:</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Will use the recommended Phase 2 doses determined in the Phase 1 portion</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Ibrutinib</intervention_name>
    <arm_group_label>Phase 1</arm_group_label>
    <arm_group_label>Phase 2: Follicular lymphoma expansion cohort:</arm_group_label>
    <arm_group_label>Phase 2: Diffuse large B-cell lymphoma expansion cohort:</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>MEDI4736</intervention_name>
    <arm_group_label>Phase 1</arm_group_label>
    <arm_group_label>Phase 2: Follicular lymphoma expansion cohort:</arm_group_label>
    <arm_group_label>Phase 2: Diffuse large B-cell lymphoma expansion cohort:</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Pathologically documented relapsed or refractory diffuse large B-cell lymphoma (DLBCL)
             or follicular lymphoma (FL)

          -  Measurable disease sites on CT scan (&gt;1.5 cm in longest dimension)

          -  Adequate hematologic function:

               1. Absolute Neutrophil Count &gt;1500 cells/mm3

               2. Platelets &gt;50000 cells/mm3

               3. Hemoglobin &gt;8.0 g/dL

          -  Adequate hepatic and renal function:

               1. AST or ALT ≤2.5 x ULN

               2. Bilirubin ≤1.5 x ULN

               3. Estimated creatinine clearance (Cockcroft-Gault) &gt;40 mL/min

          -  ECOG 0 or 1

        Exclusion Criteria:

          -  Received prior therapies: ibrutinib, or other BTK inhibitor and/or anti-PD1,
             anti-PD-L1, anti-PD-L2, anti-CD137, or CTLA-4 antibody

          -  Requires treatment or prophylaxis with a strong cytochrome P450 (CYP) 3A inhibitor

          -  Primary CNS lymphoma or evidence of CNS involvement by lymphoma
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Site-0397</name>
      <address>
        <city>Birmingham</city>
        <state>Alabama</state>
        <zip>35294</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site-0047</name>
      <address>
        <city>Duarte</city>
        <state>California</state>
        <zip>91010</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site-0038</name>
      <address>
        <city>Stanford</city>
        <state>California</state>
        <zip>94305</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site-0388</name>
      <address>
        <city>Miami</city>
        <state>Florida</state>
        <zip>33136</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site-0126</name>
      <address>
        <city>Chicago</city>
        <state>Illinois</state>
        <zip>60637</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site-0020/0173</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02114</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site-0729</name>
      <address>
        <city>Ann Arbor</city>
        <state>Michigan</state>
        <zip>48109</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site-0130</name>
      <address>
        <city>Detroit</city>
        <state>Michigan</state>
        <zip>48201</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site-0343</name>
      <address>
        <city>Hackensack</city>
        <state>New Jersey</state>
        <zip>07601</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site-0402</name>
      <address>
        <city>Philadelphia</city>
        <state>Pennsylvania</state>
        <zip>19104</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site-0114</name>
      <address>
        <city>Seattle</city>
        <state>Washington</state>
        <zip>98104</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>July 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>March 4, 2015</study_first_submitted>
  <study_first_submitted_qc>March 23, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">March 27, 2015</study_first_posted>
  <last_update_submitted>July 5, 2017</last_update_submitted>
  <last_update_submitted_qc>July 5, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">July 6, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lymphoma</mesh_term>
    <mesh_term>Lymphoma, Follicular</mesh_term>
    <mesh_term>Lymphoma, B-Cell</mesh_term>
    <mesh_term>Lymphoma, Large B-Cell, Diffuse</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Antibodies, Monoclonal</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

